VNAR · TfR1 · BBB
Science & TXP1
A brain-selective shuttle designed to carry biotherapeutics across the blood–brain barrier — described here with the context each claim needs.
Platform attributes, as described by the company
- 01
Deimmunised VNAR scaffold
A shark-derived single-domain antibody, engineered for therapeutic use.
Does not by itself establish absence of human immunogenicity.
- 02
TfR1 targeting
Binds transferrin receptor 1 for receptor-mediated transcytosis.
Mechanism description; no structural data shown here.
- 03
>40-fold brain delivery in primates
Improved delivery to brain parenchyma, per the company.
Non-human primate exposure. Comparator, payload, dose and time must accompany reuse.
- 04
Brain selectivity
The company reports no accumulation in named peripheral organs.
Study-dependent biodistribution; an earlier TXB2 study noted a lung exception.
- 05
Human receptor cross-reactivity
Binding relevant to translation.
Not demonstrated delivery or efficacy in patients.
- 06
Optimised formats & kinetics
Formats engineered for prolonged brain exposure.
Platform description.
Mouse-model surrogate
The company also offers a surrogate brain-selective shuttle for mouse models. Results with TXB2 or TXB4 are not direct TXP1 validation.
“Ready for Clinical Application”
Current company wording on its website. It is positioning — not an IND clearance, clinical-stage status or a study in patients.
Not established by the reviewed material
- An approved medicine
- Clinical benefit in humans
- A universally superior shuttle
- Regulatory approval to begin Phase I
Interactive · 360°
The TXP1 platform, step by step
Rotate the conceptual model, or move through six stages. Every fact is in the text beside it; the 3D is illustrative only.
Stage 01 / 06
The blood–brain barrier challenge
The BBB limits entry of large biotherapeutics into the brain. Delivering payloads across it is the problem Ossianix addresses.
Evidence & scope
High-level context from the company’s Science & Technology page.
Text version of all stages
01 · The blood–brain barrier challenge
The BBB limits entry of large biotherapeutics into the brain. Delivering payloads across it is the problem Ossianix addresses.
High-level context from the company’s Science & Technology page.
02 · TXP1 brain-selective shuttle
TXP1 is presented as a Brain-Selective Shuttle built on a deimmunised single-domain VNAR antibody scaffold.
Company description. Deimmunisation does not establish absence of human immunogenicity.
03 · TfR1 / receptor-mediated transcytosis
TXP1 targets transferrin receptor 1 (TfR1) to engage receptor-mediated transcytosis across the BBB.
Mechanism as described by the company. The model does not show a real receptor structure, affinity or kinetics.
04 · Biotherapeutic payload transport
The shuttle is fused or conjugated to therapeutic payloads, such as antibodies or oligonucleotides, to be carried into the brain.
Payload performance depends on cargo, dose and timepoint; no universal result is implied.
05 · Preclinical evidence
The company states TXP1 improves delivery to brain parenchyma in primates by more than 40-fold. Published mouse studies cover the related TXB2 and TXB4 variants.
Non-human primate, company-reported exposure. Not efficacy, safety or human data. A 2020 release reported >30-fold in hippocampus under specific conditions.
06 · Platform & pipeline opportunities
The published pipeline pairs TXP1 with TrkB (Parkinson’s), CD20 (multiple sclerosis), Her2 (neuro-oncology) and two undisclosed oligo programmes.
All preclinical. The chart shows IND/Phase I columns but no programme in Phase I.
All four studies are preclinical. They do not establish clinical efficacy or regulatory authorisation, and TXB2/TXB4 results are not human TXP1 trials.
Publications →